Dare Bioscience, Inc. quarterly report, Q1 FY2024

Daré Bioscience, Inc. — Q1 2024 Form 10-Q

Reporting period: Three months ended March 31, 2024. Daré is a women’s-health biopharmaceutical company with one operating segment, focused primarily on developing product candidates. Its FDA-approved product XACIATO is commercialized by Organon; Daré reported only limited royalty revenue in the quarter.

Financial performance and liquidity

MetricQ1 2024Q1 2023
Revenue$9,302$0
Operating expenses$6.03 million$8.38 million
Loss from operations$(6.02) million$(8.38) million
Other income (expense)$(733,000)$340,000
Net loss$(6.76) million$(8.04) million
Basic and diluted loss per share$(0.07)$(0.09)
Cash used in operating activities$(6.81) million$(16.12) million

Operating expenses fell 28% year over year, led by lower research and development spending; the reduction partly reflected completion of the Sildenafil Cream Phase 2b study, while Ovaprene Phase 3 and related manufacturing and regulatory costs increased. Net loss improved 16%, despite a swing in other income/expense, which management attributed mainly to a $600,000 fixed-asset disposal loss and lower interest earned on cash.

At March 31, cash and cash equivalents were $3.63 million, total assets $13.01 million, total liabilities $24.01 million, and working capital deficit approximately $7.7 million. The balance sheet showed a $4.12 million liability from the sale of future royalties and lease liabilities totaling approximately $1.64 million. Deferred grant funding liabilities were $11.84 million; grant cash is largely restricted to specified development costs. The company reported a $178.0 million accumulated deficit and substantial doubt about its ability to continue as a going concern.

Material changes and financing

  • After quarter-end, on April 29, 2024, XOMA paid Daré $22.0 million under royalty purchase agreements. Daré transferred to XOMA its post-April 1 XACIATO royalties and potential milestones, 25% of a potential $20 million Bayer payment tied to Ovaprene, and synthetic royalties on future Ovaprene and Sildenafil Cream sales. Contingent payments to Daré depend on XOMA collections exceeding specified thresholds.
  • The company also received $1.0 million in April under its DARE-LARC1 grant. Despite these receipts, management stated that available cash remained insufficient to meet working-capital and other liquidity needs for at least the next 12 months from the financial statements’ issuance date.
  • Q1 ATM sales raised approximately $215,000 gross through issuance of 607,968 shares. At March 31, 100.58 million shares were outstanding; 26.88 million potential shares from options and warrants were excluded from diluted EPS as anti-dilutive.
  • Daré had previously received $5.0 million from United in Endeavour (UiE) in exchange for a portion of XACIATO royalties. The related liability was $4.12 million at quarter-end. XOMA may repay and retire the UiE obligation; Daré may not draw additional UiE funding without XOMA’s consent.

Outlook, programs, and risks

  • Daré expects 2024 research and development expenses to be considerably below 2023, with spending focused primarily on the Ovaprene pivotal Phase 3 study and advancing Sildenafil Cream toward Phase 3. General and administrative expenses are expected to be consistent with 2023.
  • The Ovaprene Phase 3 study is underway, targeting approximately 250 participants completing 13 menstrual cycles. Daré expects to pay the remaining $500,000 under its NICHD study agreement in Q3 2024; additional study costs may arise. Bayer may decide whether to make its license effective after the pivotal trial, including by paying $20 million.
  • Following an FDA end-of-Phase 2 meeting, Daré reported alignment on key elements of a Sildenafil Cream Phase 3 program. It expected further FDA feedback in Q2 2024. Two Phase 3 studies are required to support an NDA; management estimated each would cost approximately $15 million. Daré said it would not begin certain other planned studies until it secured additional capital.
  • In January 2024, Nasdaq granted an exception through July 15, 2024 to regain compliance with the $1.00 minimum bid-price requirement, subject to specified reverse-stock-split approvals and implementation. Failure to meet the conditions could result in delisting.
  • Key risks include inability to raise sufficient capital on acceptable terms, clinical or regulatory setbacks, reliance on collaborators and grant funding, commercialization and reimbursement uncertainty, and the possibility that XACIATO sales or future pipeline products do not generate expected proceeds. The filing states that the XOMA Revenue Sharing Threshold may never be reached, so Daré may receive no contingent future income under that arrangement.

Important facts for investors to verify

  • Whether the April XOMA proceeds and subsequent funding improve liquidity enough to address the company’s stated going-concern shortfall.
  • Cash burn, grant restrictions, and the timing and availability of additional financing; reported cash includes funds largely committed to grant-funded programs.
  • Ovaprene Phase 3 enrollment, costs, results, and Bayer’s decision on its license; and FDA feedback and funding plans for Sildenafil Cream Phase 3.
  • Organon’s XACIATO commercial performance and the thresholds and payment mechanics governing any future contingent receipts from XOMA.
  • Nasdaq bid-price compliance and any reverse-stock-split action required by the July 15, 2024 deadline.
  • Potential dilution from equity issuance, outstanding options and warrants, and future financing arrangements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.